Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Protagenic Therapeutics Inc (PTIXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: PTIXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -75% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.38 | 52 Weeks Range 0.00 - 0.24 | Updated Date 05/24/2025 |
52 Weeks Range 0.00 - 0.24 | Updated Date 05/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -189.6% | Return on Equity (TTM) -512.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 491613 |
Shares Outstanding - | Shares Floating 491613 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Protagenic Therapeutics Inc
Company Overview
History and Background
Information on Protagenic Therapeutics Inc. is limited. Available data suggests they are a biotechnology company focused on developing peptide therapeutics. Further details about their founding year and specific milestones are not readily available publicly.
Core Business Areas
- Peptide Therapeutics Development: Focuses on research, development, and potential commercialization of novel peptide therapeutics for various diseases. Specific therapeutic areas are not publicly available.
Leadership and Structure
Information on Protagenic Therapeutics Inc.'s leadership team and organizational structure is not readily available in public sources.
Top Products and Market Share
Key Offerings
- PT-101: [PT-101 is a potential therapy targeting a novel mechanism of action. Clinical trial data (if any) and market share information are not publicly available. Competitors will depend on the indication PT-101 aims to treat. Common competitors in the pharmaceutical/biotech space would include major pharma companies]
- PT-201: [PT-201 is a another potential therapy targeting a novel mechanism of action. Clinical trial data (if any) and market share information are not publicly available. Competitors will depend on the indication PT-101 aims to treat. Common competitors in the pharmaceutical/biotech space would include major pharma companies]
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high risk, high reward ventures focused on developing innovative therapies. It is heavily regulated and requires significant capital investment.
Positioning
Protagenic Therapeutics Inc. is positioned as a development-stage biotechnology company. Their competitive advantage, if any, lies in their proprietary peptide technology and ability to develop novel therapeutics.
Total Addressable Market (TAM)
The TAM depends entirely on the therapeutic areas they are targeting. The global pharmaceuticals market is in the trillions. Protagenic's position within this market is currently undefined due to its early stage.
Upturn SWOT Analysis
Strengths
- Novel peptide technology platform
- Potential for first-in-class therapeutics
- Focused research and development efforts
Weaknesses
- Early-stage company with limited resources
- Dependence on successful clinical trials
- High risk of drug development failure
- Limited public information available
Opportunities
- Partnerships with larger pharmaceutical companies
- Successful clinical trial outcomes
- Expansion into new therapeutic areas
- Venture Capital Funding
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent disputes
- Inability to secure funding
Competitors and Market Share
Key Competitors
- AMGN
- GILD
- PFE
- MRK
- LLY
Competitive Landscape
Protagenic faces intense competition from larger, more established pharmaceutical and biotechnology companies. Their success depends on the clinical success of their lead compounds and ability to secure funding. They need to innovate and protect their position.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is unavailable due to the company's limited public profile.
Future Projections: Future growth projections are not available without detailed financial information and analyst coverage.
Recent Initiatives: Information on recent strategic initiatives is not readily available in public sources.
Summary
Protagenic Therapeutics is an early-stage biotech company focusing on peptide therapeutics; due to lack of sufficient publicly available information, a thorough assessment of the companyu2019s strength is challenging, but the company shows promise in the therapeutics market. Protagenicu2019s future success depends heavily on successful clinical trials and securing sufficient funding to advance their pipeline, and the companies ability to deliver on the promice of PT-101. They must look out for regulatory hurdles.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Publicly available press releases
- Company websites
- SEC filings (where available)
- Industry reports
- Market Research
Disclaimers:
The information provided is based on limited publicly available data and should not be considered financial advice. This analysis is for informational purposes only and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protagenic Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-04-27 | President, CEO & Director Mr. Barrett Evans | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.protagenic.com |
Full time employees 1 | Website https://www.protagenic.com | ||
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.